Fig. 2From: Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective studyProgression-free survival time in the two groupsmPFS: TACE + Sunitinib group, 15.6 months (95% CI 14.9–17.1 months); Sunitinib group, 10.9 months (95% CI 8.9–11.1 months).Back to article page